Ragosa Mark, Chief Financial Officer of Kiniksa Pharmaceuticals (KNSA), has demonstrated a clear selling bias in recent insider transactions, with $6.3 million in total sales outweighing $2.4 million in purchases across 29 reported trades. All activity has been concentrated in KNSA shares, with no transactions in other securities. The most recent filings show an acceleration of disposals, including eight sales since December 2025 totaling approximately $4.8 million. Notable transactions include a $1.78 million sale on December 8, 2025, followed by two March 2026 disposals valued at $866,583 and $819,574. Smaller sales in February 2026—$381,719 and $390,535—were accompanied by derivative transactions marked as "M" (likely option exercises).
The pattern shows Ragosa consistently reducing his position through both open-market sales and derivative transactions, with only minimal purchases. The largest single sale occurred in December 2025, while the most concentrated selling activity took place on March 9, 2026, with four derivative transactions and two open-market sales totaling over $2.2 million. Earlier activity includes a $814,706 sale in November 2025 and smaller transactions dating back to September 2025. The absence of any recent buys and the sustained selling trend suggest a directional reduction in exposure to KNSA shares over the past seven months.
AI-assisted summary